PRODUCT INFORMATION

Vodobatinib

Item No. 46902

CAS Registry No.:	1388803-90-4
Formal Name:	2-chloro-6-methyl-benzoic acid 2-[4-methyl-3-[2-(3-quinolinyl)ethynyl]benzoyl]hydrazide
Synonym:	K0706
MF:	$C_{27}H_{20}ClN_3O_2$
FW:	453.9
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Vodobatinib is supplied as a solid. A stock solution may be made by dissolving the vodobatinib in the solvent of choice, which should be purged with an inert gas. Vodobatinib is soluble (≥10 mg/ml) in DMSO.

Description

Vodobatinib is an inhibitor of Bcr-Abl.[1] It inhibits the proliferation of Ba/F3 cells expressing Bcr-Abl (IC_{50} = 7 nM) and those individually expressing 21 clinically relevant Bcr-Abl mutants (IC_{50}s = 2-82 nM) but is less potent against Ba/F3 cells expressing Bcr-Abl^{L248R}, Bcr-Abl^{Y253H}, Bcr-Abl^{E255V}, or Bcr-Abl^{T315I} (IC_{50}s = 167, 154, 165, and 1,967 nM, respectively). Vodobatinib induces intracellular accumulation of ATP-binding cassette transporter B1 (ABCB1) and ABCG2 substrates *in vitro* and enhances apoptosis induced by the ABCB1 substrate paclitaxel (Item No. 10461) or the ABCG2 substrate topotecan (Item No. 14129) in ABCB1- and ABCG2-overexpressing cancer cell lines, respectively.[2] It also inhibits discoidin domain-containing receptor 1 (DDR1) by 87.46% at 25 µM.[3]

References

1. Antelope, O., Vellore, N.A., Pomicter, A.D., *et al.* BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia. *Exp. Hematol.* **77**, 36-40 (2019).
2. Li, Y.-C., Lin, B.-H., Murakami, M., *et al.* Vodobatinib overcomes cancer multidrug resistance by attenuating the drug efflux function of ABCB1 and ABCG2. *Eur. J. Pharmacol.* **988**, 177231 (2025).
3. Chi, X., Chen, R., Yang, X., *et al.* Discovery of novel DDR1 inhibitors through a hybrid virtual screening pipeline, biological evaluation and molecular dynamics simulations. *ACS Med. Chem. Lett.* **16(4),** 602-610 (2025).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/16/2026

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM